ECM
NGNE icon

ExodusPoint Capital Management’s Neurogene NGNE Stock Holding History

ExodusPoint Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,119
Closed -$600K – 1914
2025
Q4 		$600K Sell
29,119
-3,402
-10% -$84.7K ﹤0.01% 1146
2025
Q3 		$564K Buy
+32,521
New +$653K 0.01% 1142
2024
Q2 		– Sell
-6,382
Closed -$325K – 1823
2024
Q1 		$325K Sell
6,382
-13,924
-69% -$465K ﹤0.01% 1243
2023
Q4 		$394K Buy
+20,306
New +$291K ﹤0.01% 1102
2022
Q2 		– Sell
-774
Closed -$29K – 2269
2022
Q1 		$29K Buy
+774
New +$45.2K ﹤0.01% 2094
2021
Q4 		– Sell
-570
Closed -$82K – 2459
2021
Q3 		$82K Sell
570
-323
-36% -$49.5K ﹤0.01% 1927
2021
Q2 		$165K Buy
+893
New +$198K ﹤0.01% 2039
2020
Q2 		– Sell
-4,158
Closed -$946K – 1939
2020
Q1 		$946K Sell
4,158
-2,103
-34% -$433K 0.05% 322
2019
Q4 		$1.54M Buy
+6,261
New +$624K 0.03% 410

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ExodusPoint Capital Management's NGNE Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 29,119 shares — an estimated $600K sold.

ExodusPoint Capital Management first reported a position in NGNE in Q4 2019 and held it in 9 quarters. The position peaked at $1.54M in Q4 2019. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 29,119 Neurogene shares in Q1 2026, an estimated $600K.
  • ExodusPoint Capital Management first reported a position in Neurogene in Q4 2019 and held it in 9 quarters.
  • ExodusPoint Capital Management's Neurogene position peaked at $1.54M in Q4 2019.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.